Swiss Software Stock News

Temenos (SWX:TEMN) has just paired a first quarter earnings update with a change in its finance leadership, providing fresh information on both its recent financial performance and how the company is organizing for future execution. See our latest analysis for Temenos. At a share price of CHF75.0, the stock has recovered from a softer start to the year, with a 90 day share price return of 16.64% and a 1 year total shareholder return of 27.33%. This suggests that recent momentum has been...

What Idorsia’s new QUVIVIQ guidance tells you Idorsia (SWX:IDIA) has put QUVIVIQ at the center of its 2026 outlook, guiding for CHF 200 million in sales after releasing its first quarter results and updating progress on its broader pipeline and partnerships. See our latest analysis for Idorsia. Following the first quarter update and QUVIVIQ guidance, Idorsia’s recent share price moves look mixed, with a 30 day share price return of 8.16% but a year to date share price return of a 6.35%...

Roche Holding stock: recent move puts long term returns in context Roche Holding (SWX:ROP) has drawn attention after a recent pullback, with the stock down about 0.6% over the past day and just over 1% over the past week. For readers tracking longer horizons, the share price shows a small decline over the past month and a larger negative move over the past 3 months, while multi year total returns remain positive. See our latest analysis for Roche Holding. At a share price of CHF316.5, Roche...

In late April 2026, Sandoz Group reported Q1 results showing 3% net sales growth at constant currency, led by 18% growth in biosimilars, while also confirming its full-year 2026 outlook for mid- to high-single-digit sales growth and core EBITDA margin expansion. The company also announced a new partnership with Samsung Bioepis covering up to five biosimilar assets, a move that materially broadens its pipeline and reinforces its push into higher-value biologic medicines. We’ll now examine how...

Kuehne + Nagel International (SWX:KNIN) shares are reacting to first quarter results, where sales reached CHF 5,603 million and net income CHF 245 million, both below the CHF 6,330 million and CHF 291 million reported a year earlier. See our latest analysis for Kuehne + Nagel International. The softer first quarter figures appear to sit alongside a mixed price picture, with a 5.0% year to date share price return but a 0.01% decline in total shareholder return over the past year. This...

Huber+Suhner (SWX:HUBN) is back on investor radars after expanding its work with Microsoft on hollow core fiber, supplying cables and connectors that are already deployed within the Azure cloud network. See our latest analysis for Huber+Suhner. That Microsoft HCF agreement arrives as momentum in the shares has already been strong, with a 30 day share price return of 22.7% and a year to date gain of 48.04% alongside a 1 year total shareholder return above 200%, suggesting sentiment has shifted...

Zurich Insurance Group (SWX:ZURN) is expanding its technology footprint with a new Global Capability Centre in Hyderabad, India. The centre is aimed at supporting its AI driven transformation and broader digital ambitions across the group. See our latest analysis for Zurich Insurance Group. Despite the new capability centre and recent digital leadership changes in Asia Pacific, Zurich Insurance Group’s share price shows a 1 month share price return decline of 4.73% and a year to date share...

Dividend approval and board refresh put Galderma in focus Galderma Group (SWX:GALD) drew fresh attention after its Annual General Meeting approved a CHF 0.35 per share dividend from capital contribution reserves and confirmed new Board members, including an independent director and two L’Oréal representatives. See our latest analysis for Galderma Group. At a CHF163.8 share price, Galderma’s recent AGM outcomes appear to have supported sentiment, with 1-month and 3-month share price returns of...

Q1 trading update puts SGS (SWX:SGSN) in focus SGS (SWX:SGSN) has come onto investors’ radar after its Q1 2026 sales and trading statement call on 23 April, prompting fresh attention on how the testing, inspection and certification group is currently positioned. See our latest analysis for SGS. Following the Q1 2026 trading update, SGS’s share price at CHF84.64 reflects mixed momentum, with a 1 day share price return of 0.76% but a 90 day share price return showing an 8.79% decline, while the...

In late April 2026, SIG announced a two-phase expansion of its Querétaro plant that will double capacity to 3 billion packs annually by 2028, integrate processes like extrusion, and support nearshoring by shifting some production from Europe to Mexico. This move positions Querétaro as SIG’s main North American manufacturing hub, improving regional responsiveness for food and beverage customers while modestly increasing local employment and operational scale in Mexico. We’ll now consider how...

Wondering if Sandoz Group shares still offer value after a strong run, or if most of the opportunity is already priced in? This breakdown will help you assess how the current price compares with fundamentals. The stock last closed at CHF 62.54, with a 7 day return of a 3.1% decline, a 30 day return of 1.3%, and a 1 year return of 76.9% that has attracted significant investor attention. Recent news has focused on Sandoz Group as an established generics and biosimilars business following its...

Wondering if Logitech International at around US$76.74 is priced for opportunity or already reflects the story? This article walks you through what the numbers are actually saying about the stock today. The share price shows mixed recent returns, with 2.0% over the past week and 6.1% over the last month, set against a 3.4% decline year to date but a 25.5% gain over one year and 42.9% over three years, while the five year return stands at a 17.3% decline. Recent headlines around Logitech have...

If you are wondering whether Roche Holding is priced attractively or trading rich right now, the starting point is to look past the ticker and focus on what the current share price implies about value. Roche Holding shares recently closed at CHF318.40, with returns of 2.0% decline over 7 days, 1.2% over 30 days, 2.2% decline year to date, 21.9% over 1 year, 25.2% over 3 years, and 25.5% over 5 years. This gives you a mix of short term softness and longer term gains to interpret. Recent news...

As the pan-European STOXX Europe 600 Index experiences a decline, with defensive sectors like utilities and telecoms showing relative strength amid geopolitical tensions, investors are increasingly on the lookout for overlooked opportunities in the market. In this environment, identifying stocks with strong fundamentals and resilience to economic fluctuations can be crucial for navigating uncertainty.

Nestlé is rolling out an industry first integration between CreativeX and CreatorIQ in its creator led advertising. The company is using AI powered quality controls to bring consistent creative standards to creator campaigns across global markets. This move extends the same level of scrutiny used in traditional media to Nestlé's creator partnerships. For investors tracking SWX:NESN, this shift in creator marketing comes as the shares trade at around CHF79.05 and have seen a 3.4% gain year...

Why the latest trial results matter for Roche Holding (SWX:ROG) Roche Holding (SWX:ROG) has put fresh clinical data in front of investors, with fenebrutinib hitting primary and secondary endpoints in two Phase III trials in relapsing multiple sclerosis. This comes alongside FDA acceptance of a supplemental filing for Gazyva/Gazyvaro in systemic lupus erythematosus. The FENhance 1 and 2 studies reported that fenebrutinib cut annualised relapse rates by 51.1% and 58.5% versus teriflunomide over...

UBS Group Q1 2026 Earnings Snapshot UBS Group (SWX:UBSG) has opened Q1 2026 reporting season following a solid 2025 finish, with Q4 revenue at US$12.8 billion and basic EPS of US$0.39 anchoring the latest set of numbers. The bank reported quarterly revenue rising from US$11.4 billion in Q4 2024 to US$12.8 billion in Q4 2025, while trailing twelve month EPS reached US$2.46 alongside net income of US$7.8 billion. This provides a clear view of how earnings have moved in line with the top line...

Amrize (SWX:AMRZ) is extending its "Made in America" cement label to four additional US plants as part of a wider push into domestic manufacturing. The company is increasing investment in its US production footprint, aiming to support local jobs and reinforce supply certainty for American customers. At its recent AGM, Amrize also approved changes to its Board of Directors, updating its governance structure. With a current share price of CHF44.94, Amrize sits in the mid cap range of the...

Lonza Group (SWX:LONN) has moved into focus after joining a funded research collaboration with Simulations Plus and the U.S. Food and Drug Administration to build predictive frameworks for amorphous solid dispersion drug products. See our latest analysis for Lonza Group. Despite the new FDA-backed collaboration and recent conference appearances, Lonza Group’s 1-day share price return of 1.83% comes against a weaker backdrop. The 90-day share price return of 12.5% and the 1-year total...

Temenos AG ( VTX:TEMN ) announced strong profits, but the stock was stagnant. Our analysis suggests that shareholders...

Wondering if ABB, at a last close of CHF 77.90, still offers value after such a strong run, or if you are arriving late to the story. The share price performance has been strong, with returns of 3.2% over 7 days, 23.4% over 30 days, 27.2% year to date, 82.8% over 1 year, 156.1% over 3 years and 207.8% over 5 years. This naturally raises questions about risk and upside from here. Recent coverage has focused on ABB's position in electrification, automation and power grid technology, which ties...

Nestlé reported past first-quarter 2026 group sales of CHF 21,317 million, down from CHF 22,601 million a year earlier, while organic growth and volumes improved despite an infant formula recall and currency headwinds. At the same time, the company accelerated portfolio streamlining and cost-saving efforts, including European job cuts and potential further ice cream divestments, highlighting a sharper focus on efficiency and core categories like coffee, pet care and nutrition. We’ll now...

If you are wondering whether Amrize at around CHF44.64 is priced attractively or not, the key question is how its current share price compares with its underlying business value. Recently, the stock has been relatively steady, with a 1.1% return over the last 30 days and a 3.0% decline over the last 7 days. This may reflect shifting views on its near term prospects and risk. Recent news flow on Amrize has focused more on maintaining investor visibility than on any single transformational...

Cosmo (SWX:COPN) is back in focus after reporting 12 month Phase III results for its Clascoterone 5% topical solution in male androgenetic alopecia, highlighting long term safety, ongoing efficacy and preparation for global regulatory filings. See our latest analysis for Cosmo. The latest clinical update comes after a mixed period in the market, with a 23.6% 1 month share price return and a 16.99% 3 month decline. Meanwhile, the 1 year total shareholder return sits at 111.93%, suggesting...